Company / Accounts Receivable
Opus Genetics, Inc. Accounts Receivable History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$2.0M
FY2025
5-year range
$926.0K / $3.6M
FY2022-FY2025
Trend
-44.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $926,000 to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2025 with a 3-year CAGR of +15.4%.
Improved from $926,000 to $2M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +15.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +15.4%, indicating consistent growth.
- In FY2025, accounts receivable decreased 44.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0M | -44.0% |
| FY2024 | $3.6M | +284.8% |
| FY2023 | $926.0K | -28.7% |
| FY2022 | $1.3M | - |
| FY2021 | - | - |
| FY2013 | - | - |
| FY2011 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026